Ajanta Pharma Limited, a Rs.1,728 crore Mumbai-based specialty pharmaceutical formulation company, announced the receipt of final approval for voriconazole tablets (50mg & 200mg), from the US Food and Drug Administration (FDA). Voriconazole is a triazole antifungal for treatment of serious invasive fungal infections and the generic version of Vfend.
Voriconazole tablets is part of ever-growing portfolio of products that Ajanta has developed for the US market. To date, the US FDA has granted Ajanta Pharma 10 ANDA final approvals and 2 tentative approvals. An additional 14 ANDAs are under review with FDA.